Physician profile
Abdi Abbassi
NPI 1831183938
$5,838.59
in general payments reported to CMS, 2019-2025
25 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $495 · 2021: $603 · 2022: $1,231 · 2023: $876 · 2024: $1,052 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,091 · Debt Forgiveness: $13.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,091.27 |
| Debt Forgiveness | $13.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,669.54 | 2019-2025 | Linzess, Skyrizi, Viberzi |
| Gilead Sciences, INC. | $529.91 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $362.66 | 2021-2023 | Stelara |
| Pfizer INC. | $356.46 | 2019-2025 | |
| Janssen Biotech, INC. | $335.49 | 2020-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $221.79 | 2019-2025 | Entyvio |
| Ardelyx, INC. | $180.35 | 2022-2025 | Ibsrela |
| Medtronic, INC. | $179.71 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.66 | 2022-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $133.01 | 2024 | Rezdiffra |
| Lilly USA, LLC | $120.17 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $118.20 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $116.10 | 2022-2024 | Dupixent |
| Aimmune Therapeutics, INC. | $110.07 | 2024-2025 | Zenpep |
| Genzyme Corporation | $50.08 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $43.13 | 2023-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $33.14 | 2021 | |
| Daiichi Sankyo INC. | $28.14 | 2024 | Injectafer |
| Enterra Medical, INC. | $20.41 | 2023 | |
| Shionogi INC | $15.95 | 2020 | |
| Amgen INC. | $15.66 | 2025 | Uplizna |
| Ethicon US, LLC | $14.21 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.16 | 2020 | |
| Olympus America INC. | $13.65 | 2024 | Evis Exera III Colonovideoscope |
| Phathom Pharmaceuticals, INC. | $9.94 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdi Abbassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.